草酸艾司西酞普兰联合小剂量富马酸喹硫平治疗抑郁症的临床疗效及安全性探讨  

To Investigate the Clinical Efficacy and Safety of Escitalopram Oxalate Combined with Low Dose Quetiapine Fumarate in the Treatment of Depression

作　　者：李阳 LI Yang(Division 6,Liaoning Mental Health Center,Tieling 112300,China)

机构地区：[1]辽宁省精神卫生中心精六科,辽宁铁岭112300

出　　处：《中国医药指南》2021年第31期98-99,共2页Guide of China Medicine

摘　　要：目的探讨并分析草酸艾司西酞普兰联合小剂量富马酸喹硫平治疗抑郁症的临床疗效及安全性。方法随机挑选本院收治的抑郁症患者共94例,按数字表法分为对照组与试验组,各47例,对照组只实施草酸艾司西酞普兰治疗,在此基础上,试验组再联合实施小剂量富马酸喹硫平治疗,比较两组治疗前后SDS(抑郁自评量表)及SAS(焦虑自评量表)评分的变化,以及HAMD(汉密尔顿抑郁量表)和BPRS(简明精神病量表)评分的变化情况。结果对比治疗前两组的SDS及SAS评分,无差异(P>0.05);和治疗前相比,两组治疗后的SDS及SAS评分均明显下降,且试验组的下降幅度要大于对照组(P<0.05)。对比两组治疗前及治疗后1周的HAMD评分,无差异(P>0.05);两组治疗后2、4、8周的HAMD评分均有所改善,且试验组的改善情况明显优于对照组(P<0.05)。对比两组治疗前及治疗后1周的BPRS评分,无差异(P>0.05);两组治疗后2、4、8周的BPRS评分均有所改善,且试验组的改善情况明显优于对照组(P<0.05)。结论对抑郁症患者实施草酸艾司西酞普兰联合小剂量富马酸喹硫平治疗,临床疗效良好,能显著改善患者的焦虑、抑郁症状,且安全可靠,建议推广。Objective To investigate and analyze the clinical efficacy and safety of escitalopram oxalate combined with low dose quetiapine fumarate in the treatment of depression.Methods A total of 94 patients with depression admitted to our hospital were randomly selected and divided into control group and experimental group according to numerical table method,47 cases in each group.The control group was treated with escitalopram oxalate only.On this basis,the experimental group was treated with quetiapine fumarate in combination.The changes of SDS(Self-rating Depression Scale)and SAS(Self-rating Anxiety Scale)scores and the changes of HAMD(Hamilton Depression Scale)and BPRS(Concise Psychiatric Scale)scores before and after treatment were compared between the two groups.Results There was no difference in SDS and SAS scores between the two groups before treatment(P>0.05).Compared with before treatment,SDS and SAS scores of the two groups decreased significantly after treatment,and the decrease of the experimental group was larger than that of the control group(P<0.05).There was no difference in HAMD scores between the two groups before and one week after treatment(P>0.05).The HAMD scores of the two groups improved two weeks after treatment,four weeks and eight weeks,and the improvement of the experimental group was significantly better than that of the control group(P<0.05).There was no difference in BPRS scores between the two groups before and one week after treatment(P>0.05).The BPRS scores of the two groups improved two weeks after treatment,four weeks and eight weeks,and the improvement of the experimental group was significantly better than that of the control group(P<0.05).Conclusion Escitalopram oxalate combined with quetiapine fumarate in the treatment of depression patients has a good clinical effect,can significantly improve the anxiety and depression symptoms of patients,is safe and reliable,and is recommended to be popularized.

关 键 词：抑郁症 草酸艾司西酞普兰 小剂量富马酸喹硫平 临床疗效 安全性 

分 类 号：R749.41[医药卫生—神经病学与精神病学]